These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 17313873

  • 1. [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B].
    Yao GB, Zhu M, Wang YM, Xu DZ, Tan DM, Chen CW, Hou JL.
    Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):891-5. PubMed ID: 17313873
    [Abstract] [Full Text] [Related]

  • 2. [Analysis of a randomized, double-blind, double-dummy, controlled, multicenter study confirmed the similar therapeutic efficacies of entecavir maleate and entecavir for treatment of HBeAg-positive chronic hepatitis B].
    Xu JH, Yu YY, Si CW, Zeng Z, Li J, Mao Q, Zhang DZ, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J, Xu ZN.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):881-5. PubMed ID: 24636286
    [Abstract] [Full Text] [Related]

  • 3. [A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of HBeAg-negative chronic hepatitis B: results at week 48].
    Xu JH, Yu YY, Si CW, Zeng Z, Zhang DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jul; 20(7):512-6. PubMed ID: 23044236
    [Abstract] [Full Text] [Related]

  • 4. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP.
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [Abstract] [Full Text] [Related]

  • 5. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H.
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [Abstract] [Full Text] [Related]

  • 6. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M, Hülagü S, Akhan SC, Sentürk O, Meriç M, Cekmen M.
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [Abstract] [Full Text] [Related]

  • 7. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J, Han T, Liu L, Li Y, Li J, Li Y, Xiao SX.
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
    Lee KS, Kweon YO, Um SH, Kim BH, Lim YS, Paik SW, Heo J, Lee HJ, Kim DJ, Kim TH, Lee YS, Byun KS, Kim D, Lee MS, Yu K, Suh DJ.
    Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736
    [Abstract] [Full Text] [Related]

  • 9. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, BEHoLD AI463022 Study Group.
    N Engl J Med; 2006 Mar 09; 354(10):1001-10. PubMed ID: 16525137
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H.
    J Gastroenterol Hepatol; 2008 Sep 09; 23(9):1320-6. PubMed ID: 18554238
    [Abstract] [Full Text] [Related]

  • 11. [Investigation of entecavir medication of chronic hepatitis B patients in the Chongqing area who failed lamivudine treatment].
    Wang ZY, Zhang DZ, Shi XF, Zhou Z, Ren H.
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jan 09; 15(1):13-5. PubMed ID: 17244451
    [Abstract] [Full Text] [Related]

  • 12. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, BEHoLD AI463027 Study Group.
    N Engl J Med; 2006 Mar 09; 354(10):1011-20. PubMed ID: 16525138
    [Abstract] [Full Text] [Related]

  • 13. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
    Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U.
    Hepatology; 2010 Feb 09; 51(2):422-30. PubMed ID: 20049753
    [Abstract] [Full Text] [Related]

  • 14. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
    Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ.
    Hepatology; 2006 Dec 09; 44(6):1656-65. PubMed ID: 17133475
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
    Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group.
    Hepatology; 2008 Jul 09; 48(1):99-108. PubMed ID: 18537189
    [Abstract] [Full Text] [Related]

  • 17. [Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area].
    LI H, WANG ZY, ZHANG DZ, SHI XF, ZHOU Z, REN H.
    Zhonghua Gan Zang Bing Za Zhi; 2009 May 09; 17(5):338-41. PubMed ID: 19497197
    [Abstract] [Full Text] [Related]

  • 18. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
    Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D.
    Gastroenterology; 2002 Dec 09; 123(6):1831-8. PubMed ID: 12454840
    [Abstract] [Full Text] [Related]

  • 19. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
    Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H.
    World J Gastroenterol; 2015 Apr 21; 21(15):4644-51. PubMed ID: 25914474
    [Abstract] [Full Text] [Related]

  • 20. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD.
    Hepatobiliary Pancreat Dis Int; 2004 May 21; 3(2):188-93. PubMed ID: 15138107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.